GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...
This Chinese MIT Physicist Uses AI To Find New Drugs. Next Up: Solar Panels And EV Batteries
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
Trump's China tariffs likely to drive up drug prices, spur shortages, experts say
President Donald Trump’s executive order imposing a 10% tariff on Chinese imports is likely to drive up the cost of generic ...
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...
pharmaphorum4d
Kelun's MSD-partnered TROP2 drug gets first okay in China
The study involved only Chinese patients, so would not be suitable for marketing applications in the US. It's worth noting, however, that MSD is focusing its development efforts for the drug in ...
pharmaphorum3d
FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials
China’s emergence ... and its generalisability to a new population should be balanced against the drug’s innovation.” The problem for Lilly’s sintilimab application is that there already ...
The New York Times9d
In China, Government Data on Drugs Blocked From Public After Backlash
Criticism over how the Chinese government buys drugs for its public ... are sounding the alarm over the country’s centralized drug procurement system and the drugs on a list of medications ...
Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
PharmiWeb8d
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare for ...